An innovative trial to detect relapse in breast cancer patients with circulating tumour DNA (ctDNA) has opened at our partner hospital, The Royal Marsden NHS Foundation Trust. The TRAK-ER trial, led by researchers at The Royal Marsden and The Institute of Cancer Research, London, will establish a circulating tumour DNA (ctDNA) surveillance programme for over 1,000 patiets with ER positive breast cancer who are currently receiving hormone therapy to reduce their risk of cancer returning.

Discovery Club members gathered at the Science Museum in London to learn how our researchers are transforming cancer care for patients with innovative combination therapies.

Analysing cancer DNA in spinal fluid could speed up and improve the diagnosis of breast cancer which has spread to the brain and spinal cord, according to a new pilot study.